NDA 017447 · Pfizer
Norpace
Disopyramide Phosphate · Oral
NovelPriority reviewLast checked: Nov 19, 2026Latest source record: May 17, 2000 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1977
Sep 1, 1977
Approved uses
3
Original approval plus efficacy supplements
Registered trials
5
2 Phase 3, 1 recruiting
FAERS reports
853
470 serious, 40 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
Mortality In the National Heart, Lung and Blood Institute's Cardiac Arrhythmia Suppression Trial (CAST), a long-term, multi-center, randomized, double-blind study in patients with asymptomatic non-life-threatening ventricular arrhythmias who had had a myocardial infarction more than 6 days but less than 2 years previously, an excessive mortality or non-fatal cardiac arrest rate (7.7%) was seen in patients treated with encainide or flecainide compared with that seen in patients assigned to carefully matched placebo-treated groups (3.0%). The average duration of treatment with encainide or flecainide in this study was 10 months. The applicability of the CAST results to other populations (e.g., those without recent myocardial infarction) is uncertain. Considering the known proarrhythmic properties of Norpace or Norpace CR and the lack of evidence of improved survival for any antiarrhythmic...
What it is approved for
From the label in effect Aug 24, 2026.
INDICATIONS AND USAGE Norpace and Norpace CR are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. Because of the proarrhythmic effects of Norpace and Norpace CR, their use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of Norpace or Norpace CR treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Norpace CR should not be used initially if rapid establishment of disopyramide plasma levels is desired. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias.
Mechanism: Mechanisms of Action Norpace (disopyramide phosphate) is a Type 1 antiarrhythmic drug (i.e., similar to procainamide and quinidine). In animal studies Norpace decreases the rate of diastolic depolarization (phase 4) in cells with augmented automaticity, decreases the upstroke velocity (phase 0) and increases the action potential duration of normal cardiac cells, decreases the disparity in refractoriness between infarcted and adjacent normally perfused myocardium, and has no effect on alpha- or beta-adrenergic receptors.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 3, 1991 Supplement 48 · Efficacy
- Jul 19, 1979 Supplement 3 · Efficacy
- Sep 1, 1977 Original approval · Type 1 - New Molecular Entity · priority review
2 products under this application
- NORPACE · DISOPYRAMIDE PHOSPHATE EQ 100MG BASE · CAPSULE, ORAL · Prescription · TE AB
- NORPACE · DISOPYRAMIDE PHOSPHATE EQ 150MG BASE · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Disopyramide" as an intervention, any sponsor and status, largest first.
- Catheter Ablation Compared With Pharmacological Therapy for Atrial Fibrillation (CAPTAF Trial)Pivotal-lookingStatus unknown
Uppsala University HospitalAcademic, hospital or other
NCT02294955 · 152 participants · Start May 2008 · Primary completion Sep 2018
Drug: Amiodarone; Sotalol and 4 more · For: Atrial Fibrillation; Quality of Life
Sites: Uppsala, Sweden
CytokineticsIndustry
NCT04219826 · 96 participants · Start Jan 10, 2020 · Primary completion Feb 28, 2023
Drug: CK-3773274 (5 - 15 mg); CK-3773274 (10 - 30 mg) and 1 more · For: Hypertrophic Cardiomyopathy (HCM)
Sites: Los Angeles, California; San Francisco, California; Evanston, Illinois · 22 sites in all
- AV Node Ablation and Pacemaker Therapy Compared to Drug Therapy for Atrial Fibrillation - Pilot StudyPivotal-lookingTerminated
Mayo ClinicAcademic, hospital or other
NCT00589303 · 27 participants · Start Dec 2007 · Primary completion Jul 2011
Drug: FDA approved rate and rhythm control drugs · For: Atrial Fibrillation; Heart Failure
Sites: Scottsdale, Arizona; Evansville, Indiana; Rochester, Minnesota · 6 sites in all
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT05556343 · 18 participants · Start Jan 18, 2023 · Primary completion Aug 19, 2024
Drug: MYK-224 · For: Cardiomyopathy, Hypertrophic
Sites: La Jolla, California; Los Angeles, California; San Francisco, California · 25 sites in all
- Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM)Pivotal-lookingCompleted
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT00000556 · Start Mar 1995
Drug: amiodarone; sotalol and 10 more · For: Arrhythmia; Atrial Fibrillation; Cardiovascular Diseases and 1 more
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective140
- off label use59
- atrial fibrillation48
- dyspnoea44
- malaise43
- fatigue42
- palpitations32
- dizziness31
- asthenia27
- feeling abnormal27
- drug interaction23
- product use issue23
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 21 |
| 2005 | 36 |
| 2006 | 13 |
| 2007 | 21 |
| 2008 | 13 |
| 2009 | 13 |
| 2010 | 42 |
| 2011 | 51 |
| 2012 | 53 |
| 2013 | 26 |
| 2014 | 71 |
| 2015 | 144 |
| 2016 | 31 |
| 2017 | 46 |
| 2018 | 18 |
| 2019 | 27 |
| 2020 | 44 |
| 2021 | 35 |
| 2022 | 49 |
| 2023 | 21 |
| 2024 | 19 |
| 2025 | 40 |
| 2026 | 19 |
Recalls
2 FDA enforcement reports for this application.
Dec 2, 2015 · Class III · Terminated
Failed Dissolution Specification
May 31, 2013 · Class III · Terminated
Failed Dissolution Specification
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Norpace (Disopyramide Phosphate)
2024 spending
$9K
Beneficiaries
n/a
22 claims
Per beneficiary
n/a
$4.49 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $113,012 |
| 2021 | $117,310 |
| 2022 | $24,162 |
| 2023 | $32,331 |
| 2024 | $9,021 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Prophylactic lidocaine for myocardial infarction.
Martí-Carvajal AJ, Simancas-Racines D, Anand V, et al. · Cochrane Database Syst Rev 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Incidence, recurrence and management of electrical storm in Brugada syndrome.
El-Battrawy I, Roterberg G, Kowitz J, et al. · Front Cardiovasc Med 2022 · Systematic Review
- Disopyramide: six years' experience.
Wilson RR, Wallace AG · Angiology 1983 · Clinical Trial, Review
- Treatment of myotonia with antiarrhythmic drugs.
Kwieciski H, Ryniewicz B, Ostrzycki A · Acta Neurol Scand 1992 · Clinical Trial, Comparative Study
- The pharmacologic treatment of atrial fibrillation.
Bolognesi R · Cardiovasc Drugs Ther 1991 · Clinical Trial, Review
- Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation.
Lafuente-Lafuente C, Valembois L, Bergmann JF, et al. · Cochrane Database Syst Rev 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.